Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.
Johanna EliassonMark K HvistendahlNanna FreundFederico BolognaniChristian MeyerPalle Bekker JeppesenPublished in: JPEN. Journal of parenteral and enteral nutrition (2022)
Once-weekly 5 mg apraglutide was well tolerated in patients with SBS-II and SBS-IF and significantly improved the absorption of fluids, electrolytes, and energy.